Exchange of Modular Components Improves Success of Debridement, Antibiotics, and Implant Retention: An Observational Study of 575 Patients with Infection After Primary Total Hip Arthroplasty

Karin Svensson; Ola Rolfson; Emma Nauclér; Stergios Lazarinis; Olof Sköldenberg; Jörg Schilcher; Per-Erik Johanson; Maziar Mohaddes; Johan Kärrholm

doi:10.2106/JBJS.OA.20.00110

Exchange of Modular Components Improves Success of Debridement, Antibiotics, and Implant Retention: An Observational Study of 575 Patients with Infection After Primary Total Hip Arthroplasty

JB JS Open Access. 2020 Dec 15;5(4):e20.00110. doi: 10.2106/JBJS.OA.20.00110. eCollection 2020 Oct-Dec.

Authors

Karin Svensson^{1

2}, Ola Rolfson^{1

2}, Emma Nauclér², Stergios Lazarinis³, Olof Sköldenberg⁴, Jörg Schilcher⁵, Per-Erik Johanson^{1

2}, Maziar Mohaddes^{1

2}, Johan Kärrholm^{1

2}

Affiliations

¹ Department of Orthopedics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
² The Swedish Hip Arthroplasty Register, Gothenburg, Sweden.
³ Department of Orthopedics, Institute of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
⁴ Division of Orthopedics, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
⁵ Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Abstract

Debridement, antibiotics, and implant retention (DAIR) is a surgical treatment for periprosthetic joint infection (PJI). DAIR is a desirable treatment option from an economic and patient perspective, if successful. The aim of this observational study was to compare the rates of success, defined as no additional reoperations due to PJI, between DAIR with exchange of modular components and DAIR without exchange in patients who had first-time PJI after primary total hip arthroplasty (THA).

Methods: Patients with PJI at the site of a primary THA who were treated with DAIR in Sweden between January 1, 2009, and December 31, 2016, were identified in the Swedish Hip Arthroplasty Register. Supplementary questionnaires were sent to orthopaedic departments for additional variables of interest related to PJI. The primary end point was another reoperation due to PJI within 2 years after the first-time DAIR. DAIR with exchange was compared with DAIR without exchange using Kaplan-Meier survival analysis and Cox regression analysis.

Results: A total of 575 patients treated with DAIR for a first-time PJI at the site of a primary THA were analyzed; 364 underwent component exchange and 211 did not. The exchange of components was associated with a lower rate of reoperations due to PJI after DAIR (28.0%) compared with non-exchange (44.1%). The Kaplan-Meier implant survival estimate for exchange was 71.4% (95% confidence interval [CI] = 66.9% to 76.3%) compared with 55.5% (95% CI = 49.1% to 62.7%) for non-exchange. With the analysis adjusted for confounders, DAIR with exchange was associated with a significantly decreased risk of another reoperation due to PJI compared with non-exchange (hazard ratio [HR] = 0.51 [95% CI = 0.38 to 0.68]).

Conclusions: In patients with a first-time PJI at the site of a primary THA, DAIR with exchange of modular components was superior to non-exchange DAIR. Surgeons should strive to exchange components when they perform DAIR, but there is a need to further identify how DAIR best should be practiced and which patients benefit from it.

Level of evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.